<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793399</url>
  </required_header>
  <id_info>
    <org_study_id>ZEROLMC-01</org_study_id>
    <nct_id>NCT04793399</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients</brief_title>
  <official_title>Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Farma, S.A</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of bosutinib plus atezolizumab in first line treatment in newly diagnosis&#xD;
      chronic-phase CML patients could potentially increase molecular responses and therefore&#xD;
      treatment discontinuation probabilities in these patients. We propose an Open-Label Phase&#xD;
      Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis&#xD;
      Chronic Phase-Chronic Myeloid Leukemia Patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of bosutinib 400 mg daily in combination with atezolizumab in participants with chronic myeloid leukemia as first line treatments</measure>
    <time_frame>through study completion, approximately 2 years</time_frame>
    <description>All Adverse Events, despite their severity or causal relationship with the study medication, will be reported, graded according CTCAE v5.0 and analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Major Molecular Response (MMR) rates</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Ratio of patients that reach a Major Molecular Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Molecular Response (MR) rates</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Ratio of patients that reach a Molecular response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive</measure>
    <time_frame>at Months 6, 12 and 24</time_frame>
    <description>Percentage of patients that remain alive at different time-points over the total number or patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of confirmed MR4 and MR4.5</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Total number of patients that reach MR4 and MR4.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of confirmed MR4 and MR4.5</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Ratio of patients that reach MR4 and MR4.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Complete Cytogenetic Responses (CCyR)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Number of patients that reach a Complete Cytogenetic Responses (CCyR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of Complete Cytogenetic Response (CCyR)</measure>
    <time_frame>At 1 year</time_frame>
    <description>Ratio of patients that reach a Complete Cytogenetic Responses (CCyR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days to response (CCyR, MMR, MR4, MR4.5)</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The median time to response (CCyR, MMR, MR4, MR4.5)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall estimated probability of response (CCyR, MMR, MR4, MR4.5)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of overall surviving patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of progression-free survival patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of failure-free survival patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of event-free survival patients</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypical assays of cell characterization</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypical assays of differentiation, maturation and proliferation NK cells markers</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypical assays of CD4+ T cells activation markers</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypical assays of predictive markers of CML relapse</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Chronic Phase-Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Bosutinib-Atezolizumab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs to be administered:&#xD;
Bosutinib 400 MG/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib 400 MG Monotherapy</intervention_name>
    <description>One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy</description>
    <arm_group_label>Bosutinib-Atezolizumab Combination</arm_group_label>
    <other_name>Bosulif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection</intervention_name>
    <description>12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles</description>
    <arm_group_label>Bosutinib-Atezolizumab Combination</arm_group_label>
    <other_name>Bosulif + Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patient ≥ 18 years of age.&#xD;
&#xD;
          2. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient (or a legal representative) has been informed of all pertinent aspects of&#xD;
             the study.&#xD;
&#xD;
          3. Patients who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures&#xD;
&#xD;
          4. Newly Patient with Philadelphia chromosome positive chronic phase CML and BCR-ABL1&#xD;
             transcript detected at diagnosis.&#xD;
&#xD;
          5. ECOG Performance Status of 0, 1, or 2.&#xD;
&#xD;
          6. Adequate hepatic, renal and pancreatic function defined as:&#xD;
&#xD;
               1. Total bilirubin within normal range or Direct bilirubin ≤ 1.5 x ULN,&#xD;
&#xD;
               2. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 x upper&#xD;
                  limit of normal (ULN) or ≤5 x ULN if attributable to liver involvement of&#xD;
                  leukemia,&#xD;
&#xD;
          7. Women of childbearing potential must have a negative pregnancy test documented prior&#xD;
             enrollment. Women of childbearing potential and men must be using an adequate method&#xD;
             of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women,&#xD;
&#xD;
          2. Participation in another clinical trial with any investigational drug within 30 days&#xD;
             prior to study enrollment,&#xD;
&#xD;
          3. Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with&#xD;
             the exception of hydroxyurea,&#xD;
&#xD;
          4. Period of time since CML diagnosis longer than 6 months,&#xD;
&#xD;
          5. Hypersensitivity to the active substances or to any of the excipients of the bosutinib&#xD;
             and/or atezolizumab formulations,&#xD;
&#xD;
          6. Major surgery or radiotherapy within 14 days of enrollment,&#xD;
&#xD;
          7. Known clinically significant liver disease, including active viral, alcoholic, or&#xD;
             other hepatitis, cirrhosis, and inherited liver disease,&#xD;
&#xD;
          8. Concomitant use of or need for medications known to prolong the QTc interval,&#xD;
&#xD;
          9. Concomitant use with strong CYP3A inhibitors (ketoconazole, itraconazole,&#xD;
             clarithromycin), moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem), or&#xD;
             strong CYP3A inducers (rifampin, carbamazepine, phenytoin),&#xD;
&#xD;
         10. History of clinically significant or uncontrolled cardiac disease, including:&#xD;
&#xD;
               1. Stage II to IV congestive heart failure (CHF) as determined by the New York Heart&#xD;
                  Association (NYHA) classification system for heart failure.&#xD;
&#xD;
               2. Myocardial infarction within the previous 6 months,&#xD;
&#xD;
               3. Symptomatic cardiac arrhythmia requiring treatment,&#xD;
&#xD;
               4. Diagnosed or suspected congenital or acquired prolonged QT history or prolonged&#xD;
                  QTc. (QTcF should not exceed 500 msec),&#xD;
&#xD;
         11. Grade III or IV fluid retention,&#xD;
&#xD;
         12. Uncontrolled hypomagnesemia or uncorrected symptomatic hypokalemia, due to potential&#xD;
             effects on the QTc interval,&#xD;
&#xD;
         13. Uncontrolled or symptomatic hypercalcemia,&#xD;
&#xD;
         14. Recent or ongoing clinically significant gastrointestinal (GI) disorder e.g. Crohn's&#xD;
             Disease, Ulcerative Colitis or prior total or partial gastrectomy,&#xD;
&#xD;
         15. Autoimmune or infectious active disease that require treatment,&#xD;
&#xD;
         16. CML patient not in chronic phase at diagnosis,&#xD;
&#xD;
         17. Patients with known atypical transcript. An atypical transcript is defined by the&#xD;
             presence of any transcript in the absence of the major transcripts b3a2 (e14a2) and&#xD;
             b2a2 (e13a2) or p210 protein,&#xD;
&#xD;
         18. Patients with known resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V). It is not&#xD;
             necessary to perform mutation tests on the patient to be included in the study if they&#xD;
             were not previously performed,&#xD;
&#xD;
         19. Individuals with an active malignancy,&#xD;
&#xD;
         20. Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic&#xD;
             hepatitis B (hepatitis B surface-antigen positive) and/or hepatitis C.&#xD;
&#xD;
         21. Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that contraindicates the use of an investigational drug.&#xD;
&#xD;
         22. Patients with severe renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Begoña Maestro, PhD</last_name>
    <phone>0034911 923 700</phone>
    <phone_ext>209</phone_ext>
    <email>begona.maestro@ifth.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentín García Gutiérrez, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

